Akeso's Ivonescimab Gets Third Indication Approval in China

MT Newswires Live

Aug 13

Akeso (HKG:9926) said ivonescimab has been approved in China for a third indication, according to a Wednesday filing with the Hong Kong Exchange.

The approval covers the use of ivonescimab in combination with chemotherapy as a first-line treatment for patients with squamous non-small cell lung cancer (NSCLC).

This marks the third major authorization for an ivonescimab-containing regimen in China since the molecule's initial approval in May 2024.

The drug was previously approved in May 2024 for EGFR-mutated locally advanced or metastatic non-squamous NSCLC patients who progressed after EGFR TKI treatment, and in April 2025 as a first-line treatment for locally advanced or metastatic NSCLC with PD-L1-positive expression.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2659049182"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2659049182\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2659049182?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-13 10:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2659049182","market":"sh","top_or_hot":-1,"title":"Akeso's Ivonescimab Gets Third Indication Approval in China","media":"MT Newswires Live","content":"<html><body><p> Akeso (HKG:9926) said ivonescimab has been approved in China for a third indication, according to a Wednesday filing with the Hong Kong Exchange.</p><p>The approval covers the use of ivonescimab in combination with chemotherapy as a first-line treatment for patients with squamous non-small cell lung cancer (NSCLC).</p><p>This marks the third major authorization for an ivonescimab-containing regimen in China since the molecule's initial approval in May 2024.</p><p>The drug was previously approved in May 2024 for EGFR-mutated locally advanced or metastatic non-squamous NSCLC patients who progressed after EGFR TKI treatment, and in April 2025 as a first-line treatment for locally advanced or metastatic NSCLC with PD-L1-positive expression.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akeso's Ivonescimab Gets Third Indication Approval in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkeso's Ivonescimab Gets Third Indication Approval in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-13 10:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Akeso (HKG:9926) said ivonescimab has been approved in China for a third indication, according to a Wednesday filing with the Hong Kong Exchange.</p><p>The approval covers the use of ivonescimab in combination with chemotherapy as a first-line treatment for patients with squamous non-small cell lung cancer (NSCLC).</p><p>This marks the third major authorization for an ivonescimab-containing regimen in China since the molecule's initial approval in May 2024.</p><p>The drug was previously approved in May 2024 for EGFR-mutated locally advanced or metastatic non-squamous NSCLC patients who progressed after EGFR TKI treatment, and in April 2025 as a first-line treatment for locally advanced or metastatic NSCLC with PD-L1-positive expression.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2399975544.HKD","symbol_name":"ALLIANZ ALL CHINA EQUITY \"AT\" (HKD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2659049182","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2659049182","pubTimestamp":1786588580,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Akeso  said ivonescimab has been approved in China for a third indication, according to a Wednesday filing with the Hong Kong Exchange.The approval covers the use of ivonescimab in combination with chemotherapy as a first-line treatment for patients with squamous non-small cell lung cancer .This marks the third major authorization for an ivonescimab-containing regimen in China since the molecule's initial approval in May 2024.The drug was previously approved in May 2024 for EGFR-mutated locally advanced or metastatic non-squamous NSCLC patients who progressed after EGFR TKI treatment, and in April 2025 as a first-line treatment for locally advanced or metastatic NSCLC with PD-L1-positive expression.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2399975544.HKD":"ALLIANZ ALL CHINA EQUITY \"AT\" (HKD) ACC","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","BK1574":"生物医药B类股","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","KURE":"KraneShares MSCI All China Health Care Index ETF","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","09926":"康方生物","LU1720050803.USD":"安联全方位中国股票基金","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU1961090484.USD":"ALLIANZ ALL CHINA EQUITY \"A\" (USD) INC","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC","LU0348783233.USD":"安联东方收入型 CI A Dis美元","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","BK1161":"生物科技"},"translate_title":"Akeso的Ivonescimab在中国获得第三个适应症批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1,"KURE":0.6},"content_text":"Akeso (HKG:9926) said ivonescimab has been approved in China for a third indication, according to a Wednesday filing with the Hong Kong Exchange.The approval covers the use of ivonescimab in combination with chemotherapy as a first-line treatment for patients with squamous non-small cell lung cancer (NSCLC).This marks the third major authorization for an ivonescimab-containing regimen in China since the molecule's initial approval in May 2024.The drug was previously approved in May 2024 for EGFR-mutated locally advanced or metastatic non-squamous NSCLC patients who progressed after EGFR TKI treatment, and in April 2025 as a first-line treatment for locally advanced or metastatic NSCLC with PD-L1-positive expression.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}